NEW YORK (Reuters Health)—Methotrexate appears to increase the risk of recurrent nonmelanoma skin cancer (NMSC) in patients with rheumatoid arthritis (RA), according to a retrospective study. “We have known for some time that several of the immunosuppressive agents used to treat RA and inflammatory bowel disease (IBD) are also associated with an increased risk of…
Search results for: biosimilars
German Registry Evaluates Systemic Psoriasis Treatments
The German Psoriasis Registry, PsoBest, found conventional systemic and biologic drugs for psoriasis demonstrated relative safety from serious adverse events in patients between January 2008–December 2012…
ACR 2015: Events to Attend at 2015 ACR/ARHP Annual Meeting
Mark Your Calendars The 2015 ACR/ARHP Annual Meeting in San Francisco is just around the corner, and it’s time to start planning for what is sure to be a busy week! Below are a few events hosted by the government affairs team you don’t want to miss. Legislative Update Sunday, Nov. 8, 9:00–10:00 a.m. In…
Phase 3 Trials: Secukinumab for Psoriatic Arthritis & DA-DKP for OA
In a global Phase 3 trial, subcutaneous secukinumab proved safe and effective in patients with psoriatic arthritis. Also, a version of aspartyl-alanyl diketopiperazine, a biologic for knee OA, has entered Phase 3 trials…
Novartis Biosimilar Takes Aim at Amgen’s Enbrel
ZURICH (Reuters)—The U.S. Food and Drug Administration has accepted Novartis unit Sandoz’s regulatory submission for approval of a biosimilar copy of Amgen’s blockbuster anti-TNF drug Enbrel, the Swiss drugmaker said on Friday. Enbrel, or etanercept as the drug is known generically, is a big prize since it was the world’s fifth-biggest selling medicine in 2014…
Relapse Rates High in IBD Patients who Stop Treatment
NEW YORK (Reuters Health)—Inflammatory bowel disease (IBD) patients who achieve remission on treatment may want to go off their IBD medications. But half or more of those who do will have a relapse, according to comprehensive analysis of relevant research. “Based on the studies with extended periods of follow up, relapse rates after cessation appear…
Depression & Anxiety Linked to Poor Rheumatoid Arthritis Outcomes
NEW YORK (Reuters Health)—Rheumatoid arthritis patients with depression and anxiety symptoms may have worse outcomes and poorer response to prednisolone, a secondary analysis of the CARDERA trial has found. “The strength of association between depression/anxiety and disease activity outcomes and treatment response warrants routine screening,” the study’s lead author Faith Matcham at King’s College London…
ACR/ARHP Annual Meeting Preview
The meeting with something for everyone! Below is a sneak peek at some of the 2015 ACR/ARHP Annual Meeting’s scientific sessions and content specific to each educational track. Basic Science Track Our knowledge of autoimmunity, bone pathology and other aspects of rheumatic disease is expanding rapidly due to the important research data produced by scientists…
Arthritis May Be Worse in Poor Countries, but Seem Worse in Rich Ones
(Reuters Health)—A study of people with rheumatoid arthritis (RA) finds that those in wealthy nations are more troubled by it, even though people in poor countries have more severe symptoms. The results, tallied from 17 countries, suggest that cultural factors may influence patients’ perception of their illness, and possibly even the results of clinical trials…
Novartis Launches First U.S. Biosimilar Drug at 15% Discount
LONDON/ZURICH (Reuters)—Novartis kicked off a new era in U.S. medicine on Thursday with the launch of the first biosimilar copy of a biotechnology drug approved in the U.S., at a discount of 15% to the original. The Swiss drugmaker’s generics unit Sandoz said Zarxio, its form of Amgen’s white blood cell-boosting product Neupogen (filgrastim), would…
- « Previous Page
- 1
- …
- 22
- 23
- 24
- 25
- 26
- …
- 28
- Next Page »